| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
|
Cancer Res
|
2004
|
2.94
|
|
2
|
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
|
J Clin Oncol
|
2007
|
1.63
|
|
3
|
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
|
Leuk Lymphoma
|
2014
|
1.40
|
|
4
|
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
|
Clin Cancer Res
|
2004
|
0.94
|
|
5
|
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
|
Clin Cancer Res
|
2004
|
0.94
|
|
6
|
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
|
Clin Cancer Res
|
2012
|
0.92
|
|
7
|
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
|
Clin Cancer Res
|
2008
|
0.88
|
|
8
|
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
|
Clin Cancer Res
|
2011
|
0.86
|
|
9
|
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
|
Clin Cancer Res
|
2002
|
0.85
|
|
10
|
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
|
11
|
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.
|
Int J Cancer
|
2002
|
0.82
|
|
12
|
Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.
|
Biochem Pharmacol
|
2004
|
0.81
|
|
13
|
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.78
|
|
14
|
Identification and characterization of the canine multidrug resistance-associated protein.
|
Mol Cancer Ther
|
2002
|
0.76
|